Viktoriia Iakovleva

MD , PhD (Medicine/Hepatology/Molecular Biology)

[Viktoriia Iakovleva @v_iakovleva]

Our recent review on Gene-based therapies for steatotic liver disease (SLD) is out now in @MolTherapy

Check it out: https://t.co/KkM4ksxGQO

#GeneTherapy #SLD #LiverDisease #MolecularTherapy #SpecialIssue

[Viktoriia Iakovleva @v_iakovleva]

AASLD 2025 in Washington D.C. 🤩
Such a great experience!
Thank you @AASLDtweets

[Viktoriia Iakovleva @v_iakovleva]

🎉Excited to share that my abstract titled "Finite human hepatocyte expansion in chimeric mouse livers is not overcome by TERT overexpression" has been selected as a Poster of Distinction by @AASLDtweets

See you in Washington D.C. in November #AASLD2025

[Viktoriia Iakovleva @v_iakovleva]

Check it out 👍

And our Review ‘Gene-based therapies for statistic liver disease’ 🧬

[Molecular Therapy Family of Journals @MolTherapy]

#MolecularTherapy's Clinical gene and cell therapy special issue is a must-read that provides comprehensive updates on AAV, CAR T-cell, NK cell, RNA, and genome editing therapies (and much more) in the clinic. Read more here:

https://t.co/lfk0Z8dQqX

[Hepatic Cell News @hepaticcellnews]

Curious about #GeneTherapy for steatotic liver disease (SLD)? 🧬

@WeillCornell's Drs. Viktoriia Iakovleva and Ype P. de Jong #Review gene-based therapies for preventing the progression of SLD and enhancing long-term liver health.

📖 https://t.co/fqm1JWTb8S | @MolTherapy

[Viktoriia Iakovleva @v_iakovleva]

Contributed to this tremendous work. Please, check it out 👇

[Nature Methods @naturemethods]

This Analysis presents benchmarking results from the Singapore Nanopore Expression consortium project, including a valuable resource of datasets generated from various long-read and short-read RNA sequencing technologies.

https://t.co/zfoDNFfUAJ

[Viktoriia Iakovleva @v_iakovleva]

Looking for #PhD opportunities? Consider #SINGA #Scholarship in #Singapore to pursue your scientific dreams!

More information here: https://t.co/VIIHG49O0T

[Viktoriia Iakovleva @v_iakovleva]

4/ And most importantly, the effect of knockdown of Mfap4 is conserved in humans, which makes it a promising therapeutic option.

[Viktoriia Iakovleva @v_iakovleva]

1/ Very glad that results of my PhD work are finally out 🤩 and published in Nature Partner Journal - Regenerative Medicine : “Mfap4: a promising target for enhanced liver regeneration and chronic liver disease treatment”

https://t.co/rXqchNrnyK

[Viktoriia Iakovleva @v_iakovleva]

3/ knockdown of Mfap4 accelerates liver regeneration.
Knockdown of Mfap4 attenuates chronic liver damage.
Knockdown of Mfap4 attenuates NASH (or, as newly called, MASH)

[Viktoriia Iakovleva @v_iakovleva]

❗️Our group identified SALL4B as the dominant oncogenes isoform for the survival and tumorigenesis is SALL4-mediated cancer cells.

Check this out 👇

https://t.co/NXEBlHMPNX

[Journal of Hepatology @JHepatology]

📢New nomenclature & diagnostic criteria for #fattyliverdisease agreed by global consensus❗️

➡️#MASLD: metabolic dysfunction-associated steatotic liver disease

✅non-stigmatising
✅can improve awareness & patient identification

🔓#OpenAcces👉https://t.co/PlTfC3XWQ4

[Viktoriia Iakovleva @v_iakovleva]

Excited to participate in #EASL2023! Explore our poster “Knockdown of a novel target gene enhances liver regeneration and attenuates chronic liver damage related liver fibrosis”, WED-514-YI to know more about novel targets to treat #NASH #NAFLD

@EASLnews
@EASLedu
#LiverTwitter

[Viktoriia Iakovleva @v_iakovleva]

Can’t wait 🤩

[EASLnews @EASLnews]

🌐#Livertwitter: Can't be in Vienna for #EASLCongress 2023? Join us online from 21-24 June!

Engage in live sessions, interact with experts, and stay ahead in hepatology. Register now! 👉https://t.co/gjXY1kIBtv

[Viktoriia Iakovleva @v_iakovleva]

@palinatolmach @NTUsg @rv_inc @summit_defi Congratulations 🎊

[Viktoriia Iakovleva @v_iakovleva]

The U.S. Food and Drug Administration's reviewers flagged increased risk of diabetes and liver injury from using the oral tablets, called obeticholic acid (OCA), for the treatment of nonalcoholic steatohepatitis (NASH) ❗️

Open market for new treatments‼️

https://t.co/oxOl9X7lvs

[Viktoriia Iakovleva @v_iakovleva]

@JuliusChapiro Rather than percentage. Moreover, in the number of neutrophils are high, the next step is to identify which exact fraction of neutrophils: mature or immature . This might give more clues about disease rather than ratio alone 🤔🤔

[Viktoriia Iakovleva @v_iakovleva]

@JuliusChapiro I was thinking and reading a bit about this as well. Not sure how it is in the US, but I also know that the ratio is rarely used in practice. Normally, if the numbers of neutrophils and lymphocytes are different from normal range , clinicians might access absolute numbers rather

[Viktoriia Iakovleva @v_iakovleva]

@DrHuangDQ @_NAFLDResearch @DrLoomba @AGA_Gastro @AASLDtweets @NUSMedicine Interesting 👍So, the difference is significant or not?